



HAL
open science

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

Antonin Levy, Lizza E.L. Hendriks, Thierry Berghmans, Corinne Faivre-Finn, Matteo Giajlevra, Niccolò Giajlevra, Baktiar Hasan, Alessia Pochesci, Nicolas Girard, Laurent Greillier, et al.

► **To cite this version:**

Antonin Levy, Lizza E.L. Hendriks, Thierry Berghmans, Corinne Faivre-Finn, Matteo Giajlevra, et al.. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. European Journal of Cancer, 2019, 122, pp.109-114. 10.1016/j.ejca.2019.09.012 . hal-04508607

HAL Id: hal-04508607

<https://hal.science/hal-04508607v1>

Submitted on 29 Nov 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

Antonin Levy, MD, PhD^{1,2,3*}, Lizza E.L. Hendriks, MD, PhD^{3,4}, Thierry Berghmans, MD, PhD⁵, Corinne Faivre-Finn, MD, PhD⁶, Matteo GiajLevra, MD, PhD^{3,7}, Niccolò GiajLevra, MD, PhD^{3,8}, Baktiar Hasan, PhD⁹, Alessia Pochesci, MD⁹, Nicolas Girard, MD, PhD¹⁰, Laurent Greillier, MD, PhD¹¹, Sylvie Lantuéjoul, MD, PhD¹², John Edwards, MB, ChB, PhD, FRCS(C/Th)¹³, Mary O'Brien, MRCP, MD¹⁴, Martin Reck, MD, PhD¹⁵, Benjamin Besse, MD, PhD^{2,16}, Silvia Novello, MD, PhD¹⁷, Anne-Marie C. Dingemans, MD, PhD^{4, 18*}; On behalf of the EORTC Lung Cancer Group (EORTC LCG)

1. Department of Radiation Oncology, Gustave Roussy, Institut d'Oncologie Thoracique (IOT), INSERM U1030 Molecular Radiotherapy, Université Paris-Saclay, F-94805, Villejuif, France.
2. Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France.
3. Young Investigators EORTC Lung Cancer Group (YI EORTC LCG)
4. Department of Pulmonary Diseases, GROW - School for oncology and developmental biology, Maastricht University Medical Center+, Maastricht, the Netherlands.
5. Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
6. Division of Cancer Sciences Institute of Cancer Sciences, University of Manchester, Christie NHS Foundation Trust, Manchester, UK
7. Respiratory Oncology Unit, Department of Thoracic and Vascular disease, CHU Grenoble Alpes, Grenoble, France
8. Radiation Oncology, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy; Department of Oncology, University of Turin, Torino, Italy.
9. European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
10. Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France; University Lyon 1, Lyon, France.
11. Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
12. Department of Biopathology, Centre Léon Bérard UNICANCER, Lyon, France, Université Grenoble Alpes, INSERM U1209/CNRS 5309 Institute for Advanced Biosciences, Grenoble France.
13. Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
14. Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK.
15. LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
16. Department of Medical Oncology, Gustave Roussy, Institut d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France
17. Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy.
18. Department of respiratory medicine, Erasmus Medical Center, Rotterdam, The Netherlands

*Corresponding authors:

Antonin Levy, MD, PhD; Antonin.LEVY@gustaveroussy.fr

Prof. Anne-Marie C. Dingemans, MD, PhD; a.dingemans@mumc.nl

This study was presented at WCLC Sept 2018, Toronto, Canada.

Background: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in NSCLC. A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting.

Methods: An EORTC Lung Cancer Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus group, and several European thoracic oncology societies' members.

Results: 444 responses were analyzed (radiation oncologist: 55% [n=242], pulmonologist: 15% [n=66], medical oncologist: 14% [n=64]). 361 physicians (81%) aimed to cure sOM NSCLC patients and 82% (n=362) included the possibility of radical intent treatment in their sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1 metastasis, 42% ≤ 3 and 17% ≥ 5 metastases. 79% (n=353) stated that number of organs involved was important for sOM-d, and most (80%, n=355) considered that only ≤ 3 involved organs (excluding primary) should be included. 317 (72%) included mediastinal lymph node involvement in the sOM-d and 22% (n=70/317) counted mediastinal lymph node as a metastatic site. Most physicians completed sOM staging with brain MRI (91%, n=403) and PET-CT (98%, n=437). Pathology proof of metastatic disease was a requirement to define sOM for 315 (71%) physicians. The preferred primary outcome for sOM clinical trials was overall survival (73%, n=325).

Conclusion: Although consensual answers were obtained, several issues remain unresolved and will require further research to agree on a sOM-d.

Keywords: oligometastasis, non-small cell lung cancer, consensus.

Introduction

More than half of non–small-cell lung cancer (NSCLC) patients present with stage IV disease at diagnosis, and up to one-third of these patients have synchronous limited metastatic (oligometastatic) disease.¹⁻⁴ Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity. This state is characterized by reduced metastatic potential with a limited number of metastatic sites, which makes the local treatment of each lesion possible.⁵ Several single-arm phase 2 studies, and multiple retrospective series reported favorable outcomes in highly selected sOM NSCLC patients who received local radical treatments (LRT).^{4,6-11} Three recent small (49 to 99 patients) randomized phase 2 studies showed that progression-free survival (PFS) (and overall survival [OS] in one study)³ almost tripled with the addition of LRT to systemic therapy compared to systemic therapy alone in sOM NSCLC patients responding to first line systemic therapy.^{3,12,13}

There is however no consensus on what specific criteria constitutes sOM NSCLC. Of note, inclusion criteria for the previously cited studies were very different. The number of metastatic lesions, number of lesions per organ, type of organ specificity (e.g. inclusion of intracranial lesions or mediastinal lymph nodes) varied, resulting in difficulty comparing results of different trials. The European Organisation for Research and Treatment of Cancer Lung Cancer Group (EORTC-LCG) initiated a consensus process. A consensus group was formed aiming to agree on a common NSCLC sOM definition (sOM-d) that could be used in future clinical trials. A meeting to define the statement was planned and, as a preparation for this meeting, a systematic review,¹⁴ a survey and real-life sOM NSCLC cases were distributed. Results of this preparatory work were used to identify areas of consensus and areas for further discussion (**Figure S1**). The results of this survey are reported here.

Methods

Study design and population

An online (Google[®] form) survey developed by the EORTC-LCG was distributed on 14/12/2017 to all LCG and Radiation Oncology Group members of the EORTC. National cancer societies in Europe (medical oncology, pulmonology, radiation oncology) were also asked to circulate the survey to their members. Responses were collected until 19/02/2018.

Description of the survey

The survey was strictly confidential and anonymous. The questionnaire was divided into four sections: general questions, sOM-d, sOM staging, and expected benefit of local treatments. The questionnaire consisted of 31 questions, 4 were “tick all boxes that apply” type questions, for all other questions only one answer could be selected. An initial survey draft was reviewed by all EORTC LCG board members (n=14) and by a panel of international experts in the field (n=12). The final questionnaire was modified according to these experts’ comments and was designed to be completed in approximately 10 minutes. A copy of the full survey is available in the

Supporting Information.

Statistical analysis

The Chi-squared test was used for dichotomous variables comparison (type of specialty: radiation oncologists vs. others). A two-sided P-value <0.05 was considered significant. All analyses were performed using software SPSS version 19.

Results

General questions

A total of 444 responses were collected. Belgium (n=62, 14%), Italy (n=55, 12%), UK (n=53, 12%), Germany (n=47, 11%), and Netherlands (n=44, 10%) contributed most (**Table S1**). Physicians specialties were: radiation oncologist: 55% (n=242), pulmonologist: 15% (n=66), medical oncologist: 14% (n=64), surgeon: 7% (n=33), clinical oncologist: 7% (n=30), and others: 2% (n=9). The main representing profession differed between countries with radiation oncologists constituting almost all responders in some countries (Germany: n=46/47, 98%, Switzerland: n=24/27, 93%). Most (78%, n=346) physicians had >5 years of experience in treating NSCLC. Working environment was university hospital (46%, n=206), cancer center (23%, n=103), general public hospital (22%, n=98), and private center (8%, n=37).

Definition of synchronous oligometastatic NSCLC

A total of 81% (n=361) of physicians aimed to treat sOM NSCLC with curative intent and the same percentage acknowledged that the possibility to treat the patient with radical intent should be part of the sOM-d (no difference according to specialty) (**Figure 1 and Table S2**). The majority (77%, n=344) did not consider the patients' mutational status in case of sOM-d. The maximum number of metastases allowed in the sOM-d varied: 19%, 42%, 4%, and 17% replied ≤ 2 , 3, 4, and ≥ 5 metastases, respectively. Some (16%) did not count as long as radical treatment was possible. 80% (n=353) stated that the number of organs involved was important for the sOM-d, and most (80%, n=355) considered that only ≤ 3 involved organs (excluding the primary tumor) should be considered sOM. 75% (n=331) stated that the type of organs involved were important for the sOM-d. In general, physicians excluded organs that are not easily amenable to LRT (e.g. 316/331 (95%) excluded meningeal and 269/331 (81%) excluded pericardial metastases, **Figure S2**). Most physicians (69%, n=309) acknowledged that it would be helpful to divide sOM into oligometastatic risk groups (**Figure S3**). 384 (87%) considered pulmonary

metastasis (outside primary tumor, i.e. M1a) as a metastatic site. 317 (72%) allowed mediastinal lymph node involvement in the sOM-d but only 22% (n=70/317) of them counted mediastinal lymph node as a metastatic site. Out of respondents favoring mediastinal lymph node, 195/317 (62%) stated that there was no specific issue regarding the mediastinal lymph node volume/location as long as radical treatment was possible. Almost half of the respondents (46%, n=204) answered that the sOM-d should take into consideration total tumor volume (i.e. volume of primary+lymph nodes+metastases).

Staging of synchronous oligometastatic NSCLC

Most physicians completed sOM staging with brain magnetic resonance imaging (MRI) (91%, n=403), and ¹⁸fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET-CT) (98%, n=437) (**Figure 2 and Table S3**). For mediastinal lymph node staging, most respondents (76%, n=336/444) stated that histology/cytology should be obtained: 85% (n=285/336) in cases where PET-CT shows suspected mediastinal lymph node or in case of a central primary tumor and 15% (51/336) always performed mediastinal staging. Investigations to obtain mediastinal lymph node histology/cytology included: EUS/EBUS (endoscopic ultrasound/endobronchial ultrasound) only (61%, n=206/336) if representative material was obtained, and mediastinoscopy directly or after negative EUS/EBUS in 25% (n=84/336). Pathology proof of metastatic disease was necessary in sOM for 315/444 (71%) physicians. However, 131/315 (42%) stated that they only obtained pathological proof when no lesion was visible on CT/MRI (i.e. FDG positive lesion on PET but no tumor on CT or MRI). 256/369 (69%) always aimed to obtain pathological proof (when safely possible) in cases where only one metastasis is present, 113/369 (21%) only when no lesion is identified on MRI/CT.

Benefit of local treatments

The preferred primary outcome parameter in clinical trials of sOM was OS (73%, n=325). Long-term OS (45%, n=200), PFS (56%, n=249), and quality of life (54%, n=238) were also selected (“tick all that apply” question). 299/444 (65%) acknowledged that assessing local control after stereotactic ablative body radiotherapy (SABR) could be an issue (63% [188/299] radiation oncologists vs. 37% [111/299] other specialties, $p<0.001$) however PFS remained a reliable endpoint for 62% (n=274/444, 65% [178/274] radiation oncologists vs. 35% [96/274] other specialties, $p<0.001$)

Discussion

To the best of our knowledge, this is the first survey collecting data on sOM NSCLC. Our results highlight that for some items, consensus may easily be obtained. For example, 81% of respondents stated that the aim of OM treatment is cure, and that mandatory baseline imaging should include PET-CT and brain MRI for 98% and 91% of respondents respectively. This fits in with recent recommendations by the EORTC to include brain MRI and PET-CT in the workup of sOM NSCLC patients.¹⁵ In the recently published EORTC systematic review on sOM NSCLC, extended staging was indeed mandated in most of the studies.¹⁴ However, several discussion points for the definition of sOM remain, and these mainly include numbers of metastases, (it is suggested that SABR could also be of benefit in up to 10 brain metastases in selected patients),¹⁵ organ type with metastasis (suggestion that patients with limited pleural disease could benefit from LRT)¹⁶ and pathology requirements. This is also reflected in the systematic review,¹⁴ the three randomized trials,^{3,12,13} and case series,¹⁷ as no uniform definition of sOM NSCLC could be retrieved. To standardize future clinical trials evaluating the benefit of metastasis-directed therapy in sOM, a common definition is required.

The preferred primary outcome measure in our survey was OS, but OS was the primary outcome in only one among three randomized phase II NSCLC OM trials.^{3,12,13} Furthermore, it was recognized by 63% that evaluating local control after SABR could be problematic, and only 62% stated that PFS was a reliable endpoint after LRT.

Limitations of this survey include,¹⁸ firstly, the absence of a response rate (respondents/total number of physicians contacted), since the survey was circulated by the national societies. Secondly, we did not subdivide our questions according to mutational status or histology. We also did not ask questions regarding the use of biological markers or the type of response to first line systemic therapy as a selection criterion for LRT. These two criteria could help the clinician to better select patients more likely to benefit from LRT.¹⁹ Thirdly, we only included questions on sOM and excluded metachronous oligometastatic state or oligoprogressive disease, which hampers extrapolation to these two other states. Finally, selection bias is possible in our study as interested oncologists were more likely to respond to the survey, but we did have a large number of respondents and multiple represented disciplines. The respondents represent a specific population. Most respondents came from Western Europe and the networks used to send the questionnaire generally targeted a specific population (physician were members of scientific society or an organization that included patients in trials). It should however be emphasized that NSCLC sOM patients should preferably be treated or supervised by reference center proposing clinical trials.

Conclusion

Although consensual answers were obtained, several issues remained unresolved and were discussed during a sOM-d consensus group meeting. A consensus sOM-d is proposed by the

EORTC consensus group²⁰ to make future clinical trials more homogeneous and to guide clinicians in daily practice.

Acknowledgements

Authors would like to thank the cancer societies that helped distributing the survey to their members:

| | |
|-------------|--|
| Belgium | BACTS (Belgian Association for Cardiothoracic Surgery) BVP-SBP (Belgian Society of Pulmonary Medicine) ABRO/BVRO (Belgian Association of Oncological Radiotherapy) ELCWP (European Lung Cancer Working Party) |
| Sweden | Swedish Lung Cancer Study Group (SLUSG) |
| Germany | DEGRO (German Society for Radiotherapy and Oncology) stereotactic group |
| UK | BTOG (British Thoracic Oncology Group) |
| Israel | ISP (Israeli Society of Pulmonology) Israeli society for clinical oncology and radiation therapy |
| Netherlands | Dutch society for Cardio-Thoracic Surgery LPRL (National Platform for Lung Tumors Radiotherapy) NVALT (Dutch Association of Physicians for Pulmonary Diseases and Tuberculosis) |
| Europe | EORTC LCG (European Organisation for Research and Treatment of Cancer Lung Cancer Group) ROG (Radiation Oncology Group) ESTRO (European Society for Radiotherapy and Oncology) |

Conflict of interest

Authors declare no conflict of interest and no funding related to this study.

LH: Outside the current manuscript: research funding Roche, Boehringer Ingelheim, AstraZeneca (all institution), advisory board: Boehringer, BMS, (both institution, BMS also self), travel reimbursement: Roche, BMS (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Quadia (self)

BB: Outside the current manuscript: Institutional grants for clinical and translational research Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma.

AD: Outside the current manuscript: advisory board BMS, MSD, Roche, Eli Lilly, Takeda, Pfizer, Boehringer Ingelheim (all institution). Research grant: BMS (institution)

Acknowledgement

This publication was supported by a donation from the “La Ligue Nationale Contre le Cancer” from France through the EORTC Cancer Research Fund.

Figure legends

Figure 1: NSCLC synchronous oligometastatic definition.

Abbreviations: NSCLC, non-small cell lung cancer.

Figure 2: Synchronous oligometastatic NSCLC staging.


Abbreviations: NSCLC, non-small cell lung cancer; FDG, ¹⁸fluorodeoxyglucose; CT/MRI, computed tomography/magnetic-resonance imaging.

References


1. <http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf> (accessed 09/24/2018)
2. Eberhardt WE, Mitchell A, Crowley J, et al; International Association for Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. *J Thorac Oncol.* 2015;10:1515-22.
3. Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. *J Clin Oncol.* 2019;37:1558-1565.
4. Parikh RB, Cronin AM, Kozono DE, et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2014;89:880-7.
5. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995; 13:8.
6. Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic non small-cell lung cancer patients. *Ann Oncol.* 2014;25:1954-1959.
7. Hasselle MD, Haraf DJ, Rusthoven KE, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. *J Thorac Oncol.* 2012;7:376-381.
8. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. *Cancer.* 2012;118:2962-2970.
9. De Ruyscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). *J Thorac Oncol.* 2012;7:1547- 1555.
10. Sheu T, Heymach JV, Swisher SG, et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. *Int J Radiat Oncol Biol Phys* 2014; 90: 850–57.
11. Bauml JM, Mick R, Ciunci C et al. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. *JAMA Oncol.* 2019 Jul 11. [Epub ahead of print]
12. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. *JAMA Oncol.* 2018;4:e173501.
13. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. *Lancet.* 2019;393:2051-2058.
14. GaijLevra N, Levra MG, Durieux V, et al; European Organisation for Research and Treatment of Cancer-Lung Cancer Group (EORTC-LCG). Defining synchronous oligometastatic non-small cell lung cancer: a systematic review. *J Thorac Oncol.* 2019. pii: S1556-0864(19)30458-7.
15. DeSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research

- and Treatment of Cancer imaging group. *Eur J Cancer* 2018;91:153-163. Iida T, Shiba M, Yoshino I, Miyaoka E, et al ; Japanese Joint Committee of Lung Cancer Registry. Surgical Intervention for Non-Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004. *J Thorac Oncol*. 2015;10:1076-82.
16. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. *Lancet Oncol*. 2014;15:387-95.
 17. Hendrik LEL, Doom C, Berghmans T, et al. Defining oligometastatic non-small cell lung cancer: a simulated multidisciplinary expert opinion. *Eur J Cancer*. 2019, in press.
 18. Levy A, Faivre-Finn C, Hasan B, et al; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG). Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. *Eur J Cancer*. 2018;93:37-46.
 19. Lindsay DP, Caster JM, Wang K, et al. Prospective characterization of circulating tumor cells using a nanotechnology-based capture system in oligometastatic patients undergoing definitive radiation therapy. *J Clin Oncol* 2017; 15S:11533-11533.
 20. Dingemans AMC, Hendriks LE, Berghmans T, et al. Searching for a definition of synchronous oligometastatic (sOMD)-NSCLC: a consensus from thoracic oncology experts. *J Thoracic Oncol* 2019, 2019 Aug 6. [Epub ahead of print]


Is it your aim to cure?



Number of organs important?




Metastases




Maximum number of :

Organs



Mediastinum staging required?



Pathology proof always required?

